Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models

1 Sept 2021

Abstract excerpt

CCNE1 -amplified ovarian cancers (OVCAs) and endometrial cancers (EMCAs) are associated with platinum resistance and poor survival, representing a clinically unmet need. We hypothesized that dysregulated cell-cycle progression promoted by CCNE1 overexpression would lead to increased sensitivity to low-dose WEE1 inhibition and ataxia telangiectasia and Rad3-related (ATR) inhibition (WEE1i-ATRi), thereby optimizing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Renal and related cancers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34622231
DOI: 10.1016/j.xcrm.2021.100394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer modelsPMID 34622231Read ↗

CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombinationSemantic proximity Read ↗

Gene amplification <i>CCNE1</i> is related to poor survival and potential therapeutic target in ovarian cancerSemantic proximity Read ↗

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilitiesSemantic proximity Read ↗

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.Semantic proximity Read ↗

CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinomaSemantic proximity Read ↗

Synthetic lethality between <i>CCNE1</i> amplification and loss of <i>BRCA1</i>Semantic proximity Read ↗

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibitionSemantic proximity Read ↗

WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcomaSemantic proximity Read ↗

Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancerSemantic proximity Read ↗

Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.Semantic proximity Read ↗

COATS Identifies Copy-Number-Dependent Drivers and Enablers of Aneuploidy in CancerSemantic proximity Read ↗

R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.